
    
      Phase 1 study to assess the safety, preliminary efficacy of PD-L1 t-haNK and to determine the
      maximal tolerated dose and designate the recommended phase 2 dose for subjects with locally
      advanced or metastatic solid cancers. The study will be conducted in 2 parts: part 1 will
      involve dose escalation and part 2 will involve expansion of the recommended phase 2 dose.
    
  